Obinutuzumab is a new generation monoclonal antibody targeting CD20 on the surface of B cells, with significantly enhanced efficiency of B cell depletion. Limit cases of membranous nephropathy (MN) treated with Obinutuzumab are reported in the literature. The present study aims to explore the efficiency and safety of Obinutuzumab for MN in a retrospectively cohort from China.
No takes yet. Share an insight, caveat, or question.
CHEN et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: